Travere Therapeutics (TVTX) Change in Receivables (2014 - 2026)

Travere Therapeutics has reported Change in Receivables for 13 years, with the latest figure at $7.2 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Receivables changed 0.29% year-over-year to $7.2 million; the trailing twelve-month figure through Mar 2026 stood at $27.8 million (up 138.83% YoY), and the FY2025 full-year result was $27.8 million, up 363.62% from the prior year.
• Change in Receivables for Q1 2026 stood at $7.2 million, up from -$27.8 million in the prior quarter.
• The five-year high for Change in Receivables was $44.2 million in Q3 2025, with the low at -$27.8 million in Q4 2025.
• Historically, Change in Receivables has averaged $3.1 million across 5 years, with a median of $2.0 million in 2024.
• The largest YoY upside for Change in Receivables was 5940.36% in 2025 against a maximum downside of 1502.17% in 2025.
• Travere Therapeutics' Change in Receivables stood at $6.0 million in 2022, then soared by 32.73% to $8.0 million in 2023, then slumped by 75.1% to $2.0 million in 2024, then tumbled by 1502.17% to -$27.8 million in 2025, then jumped by 125.97% to $7.2 million in 2026.
• The last three Change in Receivables figures came in at $7.2 million (Q1 2026), -$27.8 million (Q4 2025), and $44.2 million (Q3 2025), per Business Quant data.